Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Arcus Biosciences Inc

RCUS ✗ NOT COMPLIANT ☆ Track — members

NYSE · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$29.48

▲ +2.15%

Market Cap $3.75B · Vol 296.56K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.75B

Mid Cap

Div Yield

N/A

EPS Growth

-8.33%

YoY

RSI (14)

60.15

Momentum

Beta

0.81

vs Market

52W High

$31.72

7.06% below

52W Low

$9.82

200.20% above

Volume

296.56K

Avg 316.15K

P/B

4.73

Price-to-book

ROE

-63.26%

Return on equity

Free Float

70.78%

Public shares

Shariah Compliance8 STANDARDS

✗ Arcus Biosciences Inc (RCUS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RCUS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.00%

+4.06%

+18.16%

+55.81%

YTD

+23.71%

+197.48%

+64.05%

+7.71%

Financials & Valuation

TTM · Annual

Total Revenue	$247.00M
Net Income	$-353,000,000.00
Revenue Growth (YoY)	-74.38%
Gross Margin	100.00%
Operating Margin	-156.28%
Net Profit Margin	-142.91%
ROE	-63.26%
ROA · ROIC	-30.84% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	10.36
P/B	4.73
P/FCF	N/A
EPS Growth	-8.33%
Outstanding Shares	127.33M

Technical Indicators

50-Day SMA	$27.68
200-Day SMA	$23.86
RSI (14)	60.15
Beta	0.81
52-Week High	$31.72
52-Week Low	$9.82

Volume Today	296.56K
Avg Daily Volume (30D)	316.15K
Relative Volume	0.94x
Volatility (10D)	34.01
Volatility (30D)	42.92
Free Float	70.78%

Analyst Consensus

BUY

Current Price $29.48

Mean Target $38.33

52W Low$9.82 52W High$31.72

Current

Target

$9.82 $31.72

Current Analyst target

+30.03% upside potential · 12 analysts

Identifiers

ExchangeNYSE

FIGIBBG00DQD2751

ISINUS03969F1093

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateOct 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.